Sex as a predictor of response to cancer immunotherapy.
作者信息
Claggett Brian, Tian Lu, McCaw Zachary R, Takeuchi Masahiro, Wei Lee-Jen
机构信息
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Department of Biomedical Data Science, Stanford University School of Medicine, Palo Alto, CA, USA.
出版信息
Lancet Oncol. 2018 Aug;19(8):e377. doi: 10.1016/S1470-2045(18)30517-5.
Abstract
摘要
相似文献
1
Sex as a predictor of response to cancer immunotherapy.
Lancet Oncol. 2018 Aug;19(8):e377. doi: 10.1016/S1470-2045(18)30517-5.
2
Sex as a predictor of response to cancer immunotherapy.性别作为癌症免疫治疗反应的预测指标。
Lancet Oncol. 2018 Aug;19(8):e375. doi: 10.1016/S1470-2045(18)30443-1.
3
Sex as a predictor of response to cancer immunotherapy.性别作为癌症免疫治疗反应的预测指标。
Lancet Oncol. 2018 Aug;19(8):e376. doi: 10.1016/S1470-2045(18)30483-2.
4
Sex as a predictor of response to cancer immunotherapy.
Lancet Oncol. 2018 Aug;19(8):e378. doi: 10.1016/S1470-2045(18)30531-X.
5
Sex as a predictor of response to cancer immunotherapy.
Lancet Oncol. 2018 Aug;19(8):e379. doi: 10.1016/S1470-2045(18)30445-5.
6
Sex as a predictor of response to cancer immunotherapy - Authors' reply.性别作为癌症免疫治疗反应的预测指标——作者回复
Lancet Oncol. 2018 Aug;19(8):e380-e381. doi: 10.1016/S1470-2045(18)30535-7.
7
Sex as a predictor of response to cancer immunotherapy.
Lancet Oncol. 2018 Aug;19(8):e374. doi: 10.1016/S1470-2045(18)30446-7.
8
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study.癌症家族史作为抗PD1/PD-L1药物免疫治疗的替代预测指标：FAMI-L1研究的初步报告
Immunotherapy. 2018 Jun;10(8):643-655. doi: 10.2217/imt-2017-0167. Epub 2018 Mar 22.
9
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.与癌症中抗CTLA-4治疗潜在反应相关的基因组图谱。
Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.
10
Does a patient's sex predict the efficacy of cancer immunotherapy?患者的性别能否预测癌症免疫疗法的疗效？
Lancet Oncol. 2018 Jun;19(6):716-717. doi: 10.1016/S1470-2045(18)30270-5. Epub 2018 May 16.
引用本文的文献
1
Sex-biased adaptive immune regulation in cancer development and therapy.癌症发生发展与治疗中的性别偏向性适应性免疫调节
iScience. 2022 Jul 4;25(8):104717. doi: 10.1016/j.isci.2022.104717. eCollection 2022 Aug 19.
本文引用的文献
1
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.癌症免疫疗法的疗效与患者性别：系统评价和荟萃分析。
Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16.
2
Hazards of Hazard Ratios - Deviations from Model Assumptions in Immunotherapy.风险比的危害——免疫治疗中模型假设的偏差
N Engl J Med. 2018 Mar 22;378(12):1158-1159. doi: 10.1056/NEJMc1716612.
3
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。
JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.
4
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比：在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
Zotero 插件